IoT Investors
IoT is one of the most actively funded categories on CapLink, with 859 verified investors currently backing companies in the space.
The mix is led by VC, PE/Buy-Out and Corporate VC, alongside 7 other investor types. Deal coverage spans Pre-Seed through Secondaries, with the largest concentration at Seed.
Investor headquarters cluster in United States, Canada, Germany, France and South Africa, with activity across 194 countries in total. Ticket sizes range from roughly $5K to $1170M, covering early angel cheques through to growth-stage rounds.
Use the pre-filtered database below to explore every IoT investor on CapLink, or sign up to unlock contact details, ticket sizes and detailed investment criteria.
IoT investor database
859 investors matched for IoT. Sign up to unlock contact details and full profiles.
| Investor |
|---|
![]() TPG Biotech TPG Biotech is the life sciences venture capital platform of TPG, a leading global alternative asset manager. Established in 2002, TPG Biotech focuses on investing in pharmaceutical discovery and development, medical technology, diagnostics, healthcare and pharmaceutical services, life sciences, and industrial applications of biotechnology. The firm leverages TPG's extensive resources and expertise to support companies developing disruptive science, technologies, and business models aimed at improving patient outcomes in areas with significant unmet medical needs.
TPG Biotech's investment strategy is thematic, concentrating on sectors such as oncology, autoimmune and inflammatory diseases, cardiometabolic diseases, ophthalmology, rare diseases, as well as commercial-stage medical devices and tech-enabled services. The team brings deep scientific, clinical, and operational expertise to its investments, partnering with companies from early-stage development through clinical trials to commercialization. This approach is built upon TPG's market-leading healthcare franchise, which has invested over $30 billion across the global healthcare ecosystem since 2003. |
Riot Ventures Riot Ventures invests in companies using advanced technology to modernize critical industries with a focus on defense, manufacturing, energy, and industrial automation. |
![]() Biotechnology Fund Iran Biotech Fund invest in Iran and Iran related biotechnology and pharmaceutical companies with exceptional technologies or product opportunities based on strong scientific rationale and commercial potential.
Our key asset is a unique team of nearly 25 Venture Advisers, comprised of renowned industry leaders and professionals who, together with the fund’s managing partners, provide our portfolio companies with hands-on guidance and support.
We provide our portfolio companies with the necessary resources for long-term sustainable growth. We provide them with access to network, executive talent, strategic, operational, and business development resources. |
![]() Breslin Biotech AG Breslin Biotech AG is a private equity and venture capital arm of Breslin AG specializing in direct and fund of fund investments. Within direct investments, it focuses on investments in seed, start-up, early Venture, mid venture, late venture development and expansion, spinout, venture debt, incubation, distressed, mezzanine, later stage, mature, turnaround, emerging growth, recapitalization, PIPES, industry consolidation, bridge financing, restructuring/turnaround, management buyins, and management buyouts. Within the fund of fund investment, it prefers to invest in venture capital funds, turnaround/distressed debt funds and secondary investing-limited partners interest. It seeks to invest in cleantech, energy, chemicals, industrial biotech, service providers and contract research organizations, medical devices and healthcare, agriculture, and environmental products, services, and projects, and IT industries. The firm typically invests in all sectors of life sciences with an emphasis on biopharmaceuticals, therapeutics, and drug research, discovery, development, and delivery; technology platforms that enable pharmaceutical and biotech companies to improve or accelerate drug development like genomics, drug delivery, and bioinformatics; and diagnostics like medicine, environment, food, human-kind sector, which includes areas related to social impact, technology, and quality of life. The firm primarily invests in companies based in United States, Asia, and Europe with a focus on Germany, Switzerland, and Austria. It invests between $0.5 million and $5 million and can make higher investments with involvement of some financial players. The firm takes a board seat in its portfolio companies. The firm invests through its personal capital. Breslin Biotech AG was founded in 1997 and is headquartered in Zurich, Switzerland with additional office at San Francisco, United States of America, and London, United Kingdom. |
![]() Israel Biotech Fund |
![]() Patriot Capital, L.P. Patriot Capital, L.P. is a private equity and venture capital firm specializing in investing in growth capital, mezzanine, mature, later stage and late venture investments in middle market companies, industry consolidation, turnaround, acquisition financings, leverage and management buyouts, major capital expenditures, and balance sheet recapitalizations. It operates as an SBIC. The firm typically invests in business and consumer services, consumer products, niche manufacturing and distribution, education, e-commerce, application software, transportation, and telecom services industries. It usually invests in companies based in Mid-Atlantic with a focus on Baltimore area, Midwest, and Southern United States. The firm makes business expansion equity investments between $1 million and $20 million in small and medium-sized privately held companies, typically having annual revenues between $10 million and $200 million, enterprise value between $15 million to $100 million, and EBITDA between $2 million and $20 million. It is focused on debt capital, minority & majority equity investments. The firm prefers to invest in the form of unitranche second lien and junior subordinated debt; senior debt; mezzanine and convertible debt; and preferred and common equity. Patriot Capital, L.P. was founded in 2001 and is based in Baltimore, Maryland with additional offices in Chicago, Illinois; Charlotte, North Carolina and Dallas, Texas. |
Taaleri Bioteollisuus Taaleri is a Nordic investment and asset manager that focuses on businesses with industrial-scale opportunities within bioindustry and renewable energy. We create value by combining extensive know-how, deep expertise, entrepreneurship and capital through both funds under management and direct investments. We have been a signatory of the UN Principles for Responsible Investment (PRI) since 2010, and we joined the Net Zero Asset Managers initiative in 2021. Taaleri’s vision is to become a leading investment manager operating internationally in bioindustry and renewable energy.Garantia Insurance Company is part of Taaleri Group.Read more about our business through separate LinkedIn profiles.Taaleri Energia: https://www.linkedin.com/company/taaleri-energia/Garantia: https://www.linkedin.com/company/garantia-insurance-company/ |
![]() i&i Biotech Fund I SCSp i&i Biotech Fund I SCSp is a venture capital firm specializing in startups, seed, series A, series B and early-stage investments. The firm prefers to invest in Life Sciences companies focused on drug discoveries, medical devices, medtech, diagnostics, AI, and digital health. The firm seek to invest in Europe with focus on companies based in Central and Eastern Europe region. The firm seek to invest equity between €0.15 million ($0.17 million) and €2 million ($2.34 million). i&i Biotech Fund I SCSp was founded in 2021 and is based in Luxembourg, Luxembourg with an additional office in Luxembourg, Luxembourg. |
![]() Galliott Capital Advisors Galliott Capital Advisors is a globally oriented multi-family office providing advisory solutions, wealth preservation strategies, and direct investments in public and private markets. |
![]() Advent France Biotechnology Advent France Biotechnology focuses on ground-breaking innovations in Life Sciences to address unmet medical and clinical needs, building the next generation of pioneering healthcare companies. Keeping in mind patients’ well-being, we believe in improving medical care and taking medical innovations further ahead. We work with leading research institutions and well-established technology transfer offices, with a strong network of scientific and medical partners, exploring new territories to source breakthrough medical discoveries and drive inventive Life Sciences start-ups to success. |
![]() Clal Biotechnology Industries (CBI) Clal Biotechnology Industries Ltd. is a private equity and venture capital firm specializing in development stage, pre-clinical; incubation, seed, start-up, early venture, emerging growth, mid venture, late venture, PIPEs, and growth capital stages of financing. It prefers to invest in life sciences, medical devices, biopharmaceutical technologies, and biotechnology companies. The firm seeks to invest in companies based in United States, and Israel. It takes a seat on the board of directors of the companies it invests in. It invests through personal capital of its management. The firm acts as a lead investor and major shareholder in its portfolio companies. Clal Biotechnology Industries Ltd. was founded in July, 1998 and is based in Tel Aviv, Israel. It operates as a former subsidiary of Clal Industries and Investments Ltd. |
![]() GITV Global IoT Technology Ventures |
CRB INVERSIONES BIOTECNOLÓGICAS SGECR, S.A CRB INVERSIONES BIOTECNOLÓGICAS SGECR, S.A is a venture capital firm specializing in investments in seed, startup, early stage startups and early venture stages. It typically invests in technology and healthcare companies in the pharmaceuticals, biotechnology, med tech (equip and noninvasive technologies), medical technologies, digital health, therapeutics, diagnostics and life sciences sectors with a focus on therapy, medical products, food, development of patents for new drugs or in diagnostic tests and in applications of biotechnology in agriculture, animal health, and computer. The firm also invests in Spanish companies that manufacture diagnosis and therapy products aimed at high prevalence diseases. It typically invests between €0.5 million ($0.65 million) and €3 million ($3.89 million). The firm seeks to exit its investments between three years and five years. CRB INVERSIONES BIOTECNOLÓGICAS SGECR, S.A was founded in 2001 and is based in Madrid, Spain. |
![]() DVC We invest in Fintech, IoT, web3, SaaS, B2B, Latam, Consumer, Health. |
KSP KSP Inc. is a venture capital firm specializing in incubation, seed, and early stage companies. It prefers to invests in the IT, biotechnology, healthcare, semiconductor and other high-technology sectors. The firm primarily invests in small and medium scale industries. It prefers listing in the stock market as its exit strategy. KSP Inc. was established on December 19, 1986 and is based in Kawasaki City, Japan. |
![]() PPF PPF Group is a web of teams and thousands of people contributing unique experience and expertise from an array of disciplines. Every day, they work with phenomena, facts and events that not only help to shape the world we share today, but also mould the future of markets and services.Insights is a platform where PPF drops and shares selected topics and projects from its operations that can inspire and help many others to find a way forward.Facts and StrategiesPPF Group is an international investment group founded in the Czech Republic in 1991. It has grown to manage operations in 25 countries across Europe, North America, and Asia with financial services, telecommunications, media, real estate, mechanical engineering, and biotechnology as its core lines of business. Our priority is to create value by developing innovations, implementing new technologies, and improving the quality of management.PPF’s thirty-year history, its present-day standing, and its vision tell the story of the drive, work ethic, and professionalism of the many people who work to fulfill the vision and courage of Petr Kellner, PPF’s founder.PPF Group’s values and business strategies have remained constant in the areas that matter since its inception. We believe that growth and success are nurtured by developing long-term investment projects in both traditional and new sectors and by building modern infrastructure within a digital world. Our solid foundations were built by welding Czech talent and capabilities with global opportunities.Investments into innovation and advanced technologies combined with efficient management and operations enable PFF Group companies to offer highly competitive services that are constantly honed and updated to deliver value to our customers while also often inspiring others and facilitating a maturing of the market as a whole.We are also keenly aware of the broader social responsibility we shoulder. We go out of our way in our business to support talent and unlock opportunities for those who have the courage to follow their own path, change the world for the better, and inspire others to do the same.Our StrategyWe seek out possibilities and opportunities to develop companies, commerce, and services not only in fast-developing and high-potential fields, but also in areas that may be overlooked or perceived as too risky. Our priority is to create value at the companies in which we invest. We remain undaunted by the prospect of entering new markets and new – often synergetic – fields. When considering new business, we primarily target markets with high retail potential and those with rapidly developing infrastructure, and we focus on transactions where our contribution exceeds €100 million. We prefer to act as the majority owner, but we are also keen to work with partners espousing a business philosophy that dovetails with our own. We have built and will continue to shape PPF Group as a portfolio of companies where sectoral and geographical diversification offers stability and opportunities for vertical integration.We scout companies that need to restructure as we can provide them with strong financial backing, implement strict financial and corporate discipline, introduce promising business models, and improve the quality of management. The rate of returns on our investments relies on the professionalism and knowledge of our people and on the experience and expertise we have gained in the formation and restructuring of numerous companies in Central and Eastern Europe, Russia, and Asia. Our teams, which through their efforts feed PPF’s success, share a common vision, as well as a high level of commitment, loyalty, and professionalism.No matter where we are, we strive to nurture and grow the values that underpin our approach to business. Our watchwords are readiness, responsibility, and creativity. We bring with us a spirit of enterprise, a global perspective, and the ability to spot and embrace new business opportunities. We are sensitive to and actively promote the need for sustainability and corporate social responsibility, and we respect the cultural and political differences of the markets where we operate. We foster relationships with the public sector and help build communities in all the countries where we do business. |
AICA AICA is a non-profit organization designed to foster the development of entrepreneurial environment in Armenia . It is created to help start-ups and entrepreneurs with innovative ideas find high-caliber business professionals who would invest and help steer companies in their endeavors of high impact and growth. AICA is 20 members strong and growing.
AICA brings together a very diverse group of CEOs, Entrepreneurs and Business Professionals from Armenia, Russia, Germany, Austria, Denmark, and the USA. Its members represent various industries ranging from cutting edge sphere in Biotech, Digital Healthcare, IT, Blockchain, Artificial Intelligence, Biometrics to more traditional sectors of Manufacturing, Construction, Real Estate Development, Renewable Energy, Banking, Fin-tech, Food & Beverage, Consumer Products, Logistics and Retail. AICA boasts 5 members from YPO and members from top business schools from Armenia, Europe, and USA, including 3 graduates of Harvard Business School. Members of AICA serve on Boards of Multinational Companies and run VC funds; They are Serial Entreprenuers with multiple successful companies under their belts and Top-Notch experts in Management, International and US Law, International Marketing, Sales and Distribution; They invest as Angels in companies with high growth potential and guide them through the exciting but challenging path to success; They open doors to New Markets and Clients and dedicate their Networks, Connections, and most importantly Knowledge, Experience, and Time to help companies Beat the Market Odds. |
DAAL DAAL is a Venture capital firm specializing in growth capital and emerging growth investments. The firm likely invests in Information Technology particularly in Saas (Software as a service), Iot (Internet of Things), AI (Artificial Intelligence), Fin tech, Big Data, marketplace and more products. The firm seeks to pioneer investment opportunities in the emerging technology sector within the GCC (Gulf Cooperation Council) region and beyond. DALL was founded in 2017 and is headquartered in AL Khobar, Saudi Arabia. |
![]() HCVC HCVC backs founders on a mission to industrialize scientific and technological progress, focusing on deep tech sectors including robotics, AI, biotech, and climate tech. |
![]() IPSA IPSA is a private equity and venture capital firm specializing in seed, startup, early-stage, mid venture, later stage, growth capital, and pre-IPO investments. The firm prefers to invest in life sciences, Internet, telecommunications, biotechnology, medical, energy, chemistry, information and communications technology, water purification, natural resources, cleantech, capital goods, and distribution sectors. In life science sector it further invests in clinical-stage drug development, medical devices, drug delivery, and development services. In information and communications technology sector the firm invests with a focus in content, software, enabling technology, and infrastructure. In natural resources sector it invests further in exploration and production and renewable energy and clean technology. The firm seeks to invest in companies based in European Union with a focus on France, the U.K., Germany, the Netherlands, and Denmark and it also invest occasionally in companies based in North America. It seeks to invest in the first instance between €1 million ($1.33 million) and €5 million ($6.68 million) for a minority stake in the company. It seeks to invest in companies with revenues between €10 million ($13.37 million) and €100 million ($133.73 million). The firm prefers to be the lead or a co-lead investor in its portfolio companies. It seeks to hold a board seat in its portfolio companies. The firm exits from its portfolio companies through an IPO or trade sale within five years. The firm was formerly known as Innoven Partenaires S.A. IPSA was founded in 1997 and is based in Paris, France. |
Age 1 age1 is a venture capital firm custom-built to invest in and support contrarian founders extending healthy lifespan through longevity biotech, therapeutics, and technologies. |
Baita Baita is an accelerator and venture capital firm specializing in startups and growth capital investments. It primarily invests in information technology, telecom, internet of things, agribusiness, biotechnology, technology hardware and equipment, health, life sciences, energy, oil and gas and education technology. The firm seeks to invest in Brazil. It invests in companies with a maximum of R$0.15 million ($0.04 million). The firm seeks to take minority stake between 8% and 15%. Its acceleration program typically lasts between six to twelve months. The firm invests through its personal capital. Baita was founded in 2014 and is based in Campinas, Brazil. |
CITES CITES (Spanish acronym for Centro de Innovación Tecnológica Empresarial y Social) (Social and Business Technology Innovation Hub) belonging to Sancor Seguros Group, is an investor of early- stage venture capital with capabilities to incubate and accelerate science and technology-based startups. It accompanies startups by offering support in business, management, intellectual property and technology, and provides an exclusive incubation space with access to common laboratories fully-equipped with nanotechnology, biotechnology, engineering, and ICT for up to two years. It also offers support from the corporate areas of Sancor Seguros Group.
CITES invests in verticals such as Insurtech, Fintech, ICT, Edutech, Agtech, Pharma, Healthtech and Life Science. |
LANIT LABORATORY OF NEW INFORMATION TECHNOLOGIESis Russia’s leading group of IT-companies with about three decades of successful history.The group consists of various IT-companies providing full range of IT-services. It constantly enhances the product range by implementing new cutting-edge technologies and most demanded solutions.The LANIT group of companies includes the corporate venture fund LANIT Ventures ("LANIT Ventures").The Fund invests and supports young Russian companies that develop their own software products for B2B/B2G markets and already have their first sales. The Fund finds and develops high-tech projects, significantly increasing their investment potential.The Fund's participation includes not only financing, but also sales assistance, advice on legal, financial, tax issues, protection from errors. Startups receive assistance in building a marketing strategy and communications with customers. Currently, the fund is developing projects in the field of artificial intelligence, big data, predictive analytics, fintech, virtual reality, IoT, cloud technologies, etc.The fund works in the market of B2B/B2G solutions, but as investors, we also look at B2C solutions. First of all, we are aimed at the Russian market.The goals of each of our investments in product companies are: the creation and development of a product that is in demand by a large number of customers, the withdrawal of the company to self-supine and positive cash flow and, as a result of the first two points, the growth of shareholder value.Investment check - from 15 to 300 million rubles in one project.The fund prefers to invest in high-tech startups at an early stage, because it is at this stage that it can bring them the maximum benefit - form a strategy, fit into the ecosystem, etc.The selection of projects for investment is very careful. We try to find companies that already have market-tested solutions and revenue, where product risk is minimized, but for the LANIT group of companies there is an opportunity to significantly increase sales in the framework of cooperation with such companies.We look at each company, first of all, as an independent business. All companies within the LANIT group of companies have operational freedom and are managed by a shareholder within the board of directors/shareholders. If it is effective and meaningful, then the company can integrate into existing LANIT businesses. |
![]() TEDCO Maryland Venture Fund is a private equity and venture capital firm specializing in direct and fund of fund investments. Within direct investments it makes seed, start-ups, early venture, mid venture and late venture investments. It also specializes in growth capital, bridge financing, industry consolidation, and recapitalization transactions. Within fund of fund investments it focuses on venture capital funds. The firm typically invests in companies operating in healthcare technology including healthcare equipment and supplies, diagnostics, medical testing, information technology, therapeutic devices, medical devices and instruments, software, platform, education technology, health, communications and information technology security, biotechnology, life sciences, and in companies engaged in the development of innovative and proprietary cyber security technology. It invests in companies based in Maryland. It invests between $0.1 million and $1 million per company. It seeks to invest in companies with revenues up to $1 million. It structures its investments in the form of equity and convertible debt. It seeks to invest in companies having fewer than 50 full-time employees, has been in active business not longer than five years, whose securities are not publicly traded on any exchange, and has been certified as a qualified Maryland cyber security company by the Maryland Department of Business and Economic Development. Maryland Venture Fund is based in Columbia, Maryland. |
Understanding IoT investors
What are IoT investors, and what do they look for?
Connected device businesses are judged on the whole cost of a unit across its deployed life, not on the hardware price. Investors add the device, the connectivity subscription, the cloud infrastructure to receive and store what it sends, the support burden when it stops working, and the eventual replacement. Companies that priced against the bill of materials and discovered the recurring costs later are a familiar pattern, and investors examine the full picture before assessing the product. Revenue model is the second question, and the answer determines the business. Selling devices produces one-off revenue with a support tail. Selling the outcome the device enables, whether monitoring, compliance evidence or a maintenance service, produces recurring revenue and better economics. Investors much prefer the second and will ask why you chose otherwise if you have. Third, they examine deployment friction. Devices have to be installed, connected, configured and maintained in the physical world, frequently by people who are not technical. Companies that underestimated installation find that field operations rather than manufacturing constrains their growth.
Why IoT is attracting investor interest
Product security regulation changed who can sell a connected device in Europe. Rules imposing cybersecurity requirements on products with digital elements place obligations on manufacturers covering vulnerability handling, update provision and documentation across the product lifetime. That has raised the entry bar, pushed some low-cost competitors out, and created a compliance burden that investors now factor into cost structures. The commercial argument matured alongside. Early connected device businesses sold data collection and struggled to explain what customers should do with it. What sells now is a specific outcome: predictive maintenance that reduces downtime, monitoring that satisfies a regulatory requirement, or asset tracking that reduces loss. The pitch moved from visibility to consequence. Cellular connectivity designed for low-power devices matured enough for long-lived deployments, which removed a practical obstacle for equipment expected to run for years on a battery in a location with no network infrastructure. Industrial and infrastructure buyers became the reliable customers. Consumer connected devices have had a difficult decade in Europe, with support costs and privacy concerns, while industrial deployments with a documented payback have proven considerably more durable.
Which funding stages IoT investors are active at
Funding follows deployment evidence rather than device capability. Seed rounds fund hardware development and initial deployments, and investors weigh hardware experience heavily since the discipline punishes teams from software backgrounds who underestimate manufacturing, certification and field failure. Series A requires deployments running in production with data on failure rates, installation time and what support actually costs. Investors examine whether the second deployment took less effort than the first, since bespoke installations indicate a project business rather than a product. Series B funds manufacturing scale and field operations, both capital-intensive. Working capital becomes significant because devices must be built before customers pay, and investors expect that to be financed rather than funded from equity. Where the business sells outcomes rather than devices, the company frequently retains ownership of the hardware, which means financing the deployed fleet. That structure requires asset finance and investors will ask how it is arranged. Strategic acquirers include industrial equipment manufacturers, connectivity providers and enterprise software vendors.
Typical check and round sizes in IoT
Averages across connected devices would blend consumer products, industrial sensors and infrastructure monitoring, whose economics differ enormously. The structural discipline is to model the deployed unit across its full life. Hardware cost, connectivity subscription, cloud storage and processing, support incidents, firmware maintenance obligations and replacement all continue after the sale. A company charging once for a device that generates ongoing cost has a business that gets worse as it grows, and investors identify this quickly. Certification is a real expense that founders underestimate. Radio approval, electrical safety, electromagnetic compatibility and now product security compliance all cost money and time before a device can be sold in Europe, and they recur with hardware revisions. Working capital dominates once volumes rise, since components must be purchased and devices manufactured well ahead of customer payment. Component lead times in particular have caused cash problems for companies that grew faster than they financed. If you retain ownership of deployed hardware, that fleet needs asset financing rather than equity. For comparables, use recent European rounds from companies with the same deployment model and customer type.
Types of investors active in IoT
Investors who model whole-life unit economics as a matter of routine and understand why field operations rather than manufacturing usually constrains growth. They are realistic about certification costs and support burdens that software investors overlook.
Corporate investors from manufacturers who embed connectivity in their own products. They provide deployment environments, distribution through existing channels and manufacturing capability, and they are common acquirers.
Investment arms of network operators whose services these devices consume. They can provide favourable connectivity terms and distribution into enterprise customers, which materially affects unit economics.
Lenders financing deployed hardware where the company retains ownership and charges for the service. Essential for outcome-based models, since funding a growing installed fleet from equity is prohibitively expensive.
Investors backing the platform and analytics layer rather than the devices. They apply software economics and avoid hardware exposure, so how the business is framed determines whether they engage at all.
European and national programmes supporting industrial digitalisation and infrastructure monitoring. Well suited to demonstration deployments, and some schemes subsidise the customer rather than the supplier.
What IoT investors look for in diligence
Connected device diligence is unusually physical and investors will ask about failures rather than capabilities. Field performance is examined first: how many units are deployed, for how long, what proportion have failed, what caused the failures and how they were resolved. Investors treat laboratory reliability figures as uninformative compared with deployed experience. Whole-life unit economics are rebuilt including connectivity, cloud, support and replacement, and compared against the revenue the unit produces. Companies charging once for a device with continuing costs are identified at this stage. Installation and field service capability is assessed, covering who installs, how long it takes, what training is required and whether the model scales without a technician in every region. Certification status is verified across radio, safety, electromagnetic compatibility and product security obligations, along with what happens when hardware revisions require recertification. Supply chain is reviewed for component concentration and lead times, since single-source components have stranded companies when supply tightened. Firmware update and vulnerability handling processes are examined, since European product security rules impose obligations across the supported lifetime and a company without a process carries a compliance gap. Data protection is assessed where devices collect information about people or premises.
How to build a fundraising strategy as a IoT startup
Model and present whole-life unit economics before an investor asks. Volunteering the connectivity, cloud, support and replacement costs alongside the hardware margin signals operational maturity and pre-empts the analysis that would otherwise be done less generously. Sell the outcome rather than the device wherever the customer will accept it. Recurring revenue tied to a result produces better economics, longer relationships and higher valuations, and investors will ask why you have not if you are still selling hardware outright. Arrange asset financing if you retain ownership of deployed units. A growing installed fleet funded from equity is among the most expensive structures available, and lenders exist specifically for it. Budget certification properly, including recertification on hardware revisions and the new product security obligations, which are a genuine cost rather than paperwork. Build field operations deliberately. Installation and maintenance capacity determines growth more often than demand does, and partnering with existing installer networks usually beats building your own. Design the supply chain for resilience rather than lowest cost. Component shortages have stopped companies that were otherwise performing well, and investors ask about single-source dependencies specifically.
Common mistakes founders make raising IoT capital
Pricing against the bill of materials while ignoring recurring connectivity, cloud and support costs produces a business that loses more money as it deploys more units. This is the category's defining error and it is visible immediately in whole-life analysis. Selling data collection without a decision attached leaves customers with dashboards they stop looking at. Renewal depends on the device changing something the customer does. Underestimating field installation caps growth at the rate you can deploy, which is frequently far below the rate you can sell. Treating certification as a launch task rather than a continuing obligation creates problems at every hardware revision, and the product security requirements now extend obligations across the supported life of the device. Single-sourcing critical components without alternatives has stranded companies during supply disruption, and the risk has not disappeared. Funding a deployed hardware fleet from equity in an outcome-based model dilutes founders for something a specialist lender would finance, and the requirement grows with every successful deployment.
How IoT investment differs across Europe
Germany has the largest industrial base in Europe and correspondingly the deepest market for industrial connected devices, with demanding buyers, strong engineering talent and established machinery manufacturers as partners and acquirers. The Nordics have strong positions in industrial sensing, connectivity technology and infrastructure monitoring, supported by telecommunications heritage and early adoption among utilities and industrial operators. The Netherlands combines logistics density with strong electronics and semiconductor supply chains, which supports both asset tracking applications and hardware development. France has substantial activity in industrial and infrastructure monitoring with public support for industrial modernisation, alongside a domestic connectivity industry. The UK has strength in the software and analytics layer above devices and in infrastructure monitoring, with a comparatively thin hardware manufacturing base. Italy and Spain have significant machinery and manufacturing sectors adopting connectivity, with growing local activity and less entrenched competition than northern markets. Central and Eastern Europe supplies substantial electronics manufacturing capacity and engineering talent, and increasingly hosts product companies rather than only contract manufacturing, with the advantage of proximity to Western European industrial customers.
Ready to reach IoT investors?
Create a free CapLink account to unlock full investor profiles, contact details, ticket sizes and intelligent matching.
















